ascopubs.org

Patient With HIV-Associated Plasmablastic Lymphoma Responding to Bortezomib Alone and in Combination With Dexamethasone, Gemcitabine, Oxaliplatin, Cytarabine, and Pegfilgrastim ...

The Diagnosis in Oncology article by Bibas et al entitled, "Patient With HIV-Associated Plasmablastic Lymphoma Responding to Bortezomib Alone and in Combination With Dexamethasone, Gemcitabine, ...
ascopubs.org

Toward Personalization of Cytarabine Dosing in Acute Myeloid Leukemia

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
ascopubs.org

A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.

A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
ascopubs.org

A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

Randomized comparator-controlled study evaluating efficacy and safety of pembrolizumab plus Bacillus Calmette-Guérin (BCG) in patients with high-risk nonmuscle-invasive bladder cancer (HR NMIBC): ...
ascopubs.org

Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.

Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting II.
ascopubs.org

Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial.

NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). This is an ASCO Meeting Abstract from the 2024 ...
ascopubs.org

Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase ...

Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial. This is an ASCO Meeting ...
ascopubs.org

Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer

Supported by Swim Across America, Simon and Eve Colin Foundation, Dalton Family Foundation, AACR Stand up to Cancer Colorectal Dream team, and National Cancer Institute of the National Institutes of ...
ascopubs.org

Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial.

Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting II. This abstract does not ...
ascopubs.org

Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.

BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement. Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) ...
ascopubs.org

Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202.

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma ...
ascopubs.org

Validation of a multi-modal blood-based test for the detection of colorectal cancer with sub single molecule sensitivity.

Impact of the COVID-19 pandemic on colorectal cancer (CRC) care: Data from 22 German cancer centers (CC) and the Institute of Pathology, Ruhr-University Bochum - the AIO (Working Group for Internal ...